Integrated Diagnostics Holdings Reports Strong Q1 2025 Results with 35% Revenue Growth

Integrated Diagnostics Holdings ( (GB:IDHC) ) has issued an update.

Integrated Diagnostics Holdings reported a strong start to 2025 with a 35% increase in revenue for the first quarter, reaching EGP 1,583 million. Despite a decline in net profit due to the normalization of foreign exchange gains, the company’s normalized net profit more than doubled, showcasing improved operational efficiency and strategic pricing adjustments. IDH expanded its branch network significantly, particularly in Egypt, and maintained test volumes despite seasonal slowdowns, indicating a robust market position. The company also saw notable revenue growth in Jordan and Nigeria, driven by strategic price hikes and promotional efforts.

More about Integrated Diagnostics Holdings

Integrated Diagnostics Holdings (IDH) is a leading provider of diagnostic services operating in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan. The company focuses on offering pathology and radiology services, with a significant market presence in Egypt, where it generates the majority of its revenue.

Average Trading Volume: 379,740

Technical Sentiment Signal: Strong Sell

Current Market Cap: $211.6M

See more insights into IDHC stock on TipRanks’ Stock Analysis page.